 Amyloid .beta. protein (globular assembly and uses thereof) |
| What is claimed is: 1. An isolated, soluble, non-fibrillar amyloid .beta. protein assembly ... |
|
| Chlamydia antigens and corresponding DNA fragments and uses thereof |
| The present invention provides purified and isolated polynucleotide molecules that encode the C... |
|
| Methods of treating inflammatory bowel disease using cholera toxin B subunit |
| What is claimed is: 1. A method of treating inflammatory bowel disease in a subject diagnosed with ... |
|
| Anti hepatitis C virus antibody and uses thereof |
| OF THE PRESENT INVENTION Accordingly, the technical problem of the invention is to provide means ... |
|
| Chemical and/or biological decontamination system |
| OF THE INVENTION The present invention provides a composition that is effective in the ... |
|
| Immunostimulant bacterial membrane fractions in cancer treatment |
| The invention claimed is: 1. A method of stimulating an immune response and/or inducing an ... |
|
| Cloning and characterization of a human adenylyl cyclase |
| One aspect of the invention is an isolated and purified human type VI adenylyl cyclase (hAC6) ... |
|
| Tumor antigen based on products of the tumor suppressor gene WT1 |
| What is claimed is: 1. An isolated polypeptide which consists of at most 12 contiguous amino acid ... |
|
| Methods of inhibiting GPR-9-6 function |
| The invention relates to an antibody (immunoglobulin) or functional fragment thereof (e.g., an ... |
|
|
Recombinant antibody and antibody fragment
| Details |
Inventors: Shitara, Kenya; Hanai, Nobuo; Shoji, Emi; Sakurada, Mikiko; Furuya, Akiko; Nakamura, Kazuyasu; Niwa, Rinpei; Shibata, Kenji; Yamasaki, Motoo;
Assignee: Kyowa Hakko Kogyo Co., Ltd. (Tokyo, JP)
Primary Examiner: Gambel; Phillip
Assistant Examiner: Ouspenski; Ilia
Attorney, Agent or Firm: Fitzpatrick, Cella, Harper & Scinto
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer. |
|
DETAILED DESCRIPTION OF THE INVENTION This application is based on Japanese applications No.
2000-59508 filed on Mar.
3, 2000 and No.
2000-401563 filed on Dec.
28, 2000, the entire contents of which are incorporated hereinto by reference.
Examples of the Th2-mediated immune diseases in the present invention include acute or chronic airway hypersensitivity or bronchial asthma, atopic skin diseases including atopic dermatitis, allergic rhinitis, pollinosis and the like.
Examples of the cancer in the present invention include blood cancers, and particularly leukemia.
Any recombinant antibody or the antibody fragment thereof according to the present invention (hereinafter referred to as the "antibody of the present invention") may be used, so long as it can react specifically with the extracellular domain of human CCR4.
A preferred antibody is an antibody which specifically reacts with a domain comprising positions 1-39, positions 98-112, positions 176-206 or positions 271-284 of the amino acid sequence represented by SEQ ID NO:17.
More preferred antibodies are an antibody comprising CDR1, CDR2 and CDR3 of an H chain V region having the amino acid sequences represented by SEQ ID NOs:5, 6 and 7, respectively, and CDR1, CDR2 and CDR3 of an L chain V region having the amino acid sequences represented by SEQ ID NOs:8, 9 and 10, respectively; and an antibody comprising an H chain V region having amino acids of positions 20-138 in the amino acid sequence represented by SEQ ID NO:15, and an L chain V region having amino acids of positions 20-132 in the amino acid sequence represented by SEQ ID NO:16.
Antibodies and antibody fragments in which one or more amino acids are deleted, added, substituted and/or inserted in these amino acid sequences and which specifically react with CCR4 are also included within the scope of the present invention.
In the present invention, one or more amino acid deletion, substitution, insertion or addition in the amino acid sequence means that one or more amino acids are deleted, substituted, inserted and/or added to at one or plural positions in the amino acid sequence
|
| Related patents |
|
|
Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
PspC (see FIGS. 1, 2, 3, 4, 5, 11, 12, 13, 14, 15) is one of three designations for a pneumococcal surface protein which is PspA-like, and whose gene is present in ...
|
|
|
Large DNA cloning system based on yeast artificial chromosomes
OF THE INVENTION While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter regarded as forming the present ...
|
|
|
Rat neurotrophic factor receptor, GFRα-4
OF THE INVENTION Thus, the present invention relates to a nucleic acid molecule encoding a mammalian GDNF family receptor α-4 (GFRα-4) or an immunologically ...
|
|
|
Polypeptide and protein derivatives and process for their preparation
What we claim is: 1. A method of producing a composition containing modified protein or polypeptide molecules, or salts thereof, wherein said modified protein or ...
|
|
|
Single chain MHC complexes and uses thereof
The present invention relates to novel complexes of major histocompability complex (MHC) molecules (class I or II), e.g., empty single chain MHC class II complexes, ...
|
|
|
IL-1/TNF-.alpha.-activated kinase (ITAK), and methods of making and using the same
The present invention provides nucleic acid and amino acid sequences of protein kinases, preferably human, that interact with at least one post-receptor intracellular ...
|
|
|
DNA encoding IL-1 receptor accessory protein
What is claimed is: 1. An isolated polynucleotide comprising SEQ ID NO:1 wherein the nucleic acid at 1792 is A or C. 2. An isolated polynucleotide comprising a nucleic ...
|
|
|
Human immunodeficiency virus immunogenic composition
The present invention relates to an HLA-based vaccine against HIV. Vaccines of the invention, which induce salutary anti-HIV immune responses, can be designed based on ...
|
|
|
Recombinant molecule encoding human protease nexin
We claim: 1. An isolated DNA molecule which encodes mature protease nexin-I (PN-I) alpha of FIG. 3 or PN-I beta of FIG. 4 or encodes a PN-I protein encoded by a gene ...
|
|
|
Method for design of substances that enhance memory and improve the quality of life
I claim: 1. Each of the compounds Gln Phe Phe-.gamma.-aminobutyric acid (SEQ ID NO: 20) Gln Phe Phe-.beta.-alanine (SEQ ID NO: 21) Gln Phe Phe-.delta.-aminovaleric acid (...
|
|
|
Drugs 
